You just read:

Soligenix Completes Enrollment in its Pivotal Phase 3 Clinical Trial of SGX301 in the Treatment of Cutaneous T-cell Lymphoma

News provided by

Soligenix, Inc.

Dec 03, 2019, 07:00 ET